Cancer Therapy Products Continue to Be Top Drug Class Advertising in Health Journals

by Client Services

Total print advertising dollars in professional health journals reached nearly $436 million through Q3 2013, a 6% decrease year-over-year, according to Kantar Media. The top product class continues to be Cancer Therapy with almost $35 million spent advertising in professional health journals through September. This class comprises about 8% of the market share with Anticoagulants Oral making up about 5%.

The top product classes by dollars are as follows:

Top 5 Print Ad Drug Classes (Dollars): Jan. – September 2013

#1 Cancer Therapy Products - $35 MM (+16%)

#2 Anticoagulants Oral - $21 MM (+35%)

#3 Diabetes Oral - $13 MM (+202%)

#4 Diabetes Insulin - $9 MM (-43%)

#5 Anticholinergics - $7 MM (+1,582%)

The percentage changes compare January – September 2013 to that same time period in 2012. For more information on these ad insights or other data, let one of us know.

Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date.